Abstract:Cyclotriazadisulfonamide (CADA) is a macrocyclic compound known for its unique mechanism in inhibiting HIV infection by downregulating the CD4 T-cell receptor, a crucial entry point for the virus. Unlike other antiretrovirals, CADA exhibits activity against a wide range of HIV strains, as all HIV variants require CD4 binding for infection. Furthermore, CADA has shown a synergistic effect with clinically approved anti-HIV drugs, offering potential for enhanced therapeutic strategies (Vermeire & Schols, [65]). One proposed mechanism for CADA's inhibition of the CD4 receptor involves blocking the gates of the Sec61 channel, thereby preventing its translocation. However, CADA suffers from poor solubility and bioavailability. To address this, the study aimed to design CADA analogs with improved binding to the Sec61 channel, enhanced bioavailability, and reduced toxicity. The analogs were designed using SeeSAR, with Avogadro and Meeko used for 3D configuration and pseudoatom placement, respectively. AutoDock Vina version 1.2.4 was employed to predict the binding energies of these analogs. Of the 113 analogs designed, 93 demonstrated a more negative binding energy to the Sec61 channel compared to CADA. Structure-binding energy analyses were done to the top-binding analogs to show favorable structural modifications. Enzyme-ligand interactions were analyzed to elucidate the forces contributing to these binding energies. Additionally, 33 of the 113 analogs were deemed bioavailable using a bioavailability criteria specific for macrocycles. Toxicity predictions using PASS Online and StopTox identified analogs JGL023, JGL024, JGL032, and JGL047 as potential drug candidates. Molecular dynamics simulations using Gromacs-2020.4 revealed that JGL023 and JGL032 exhibited the most favorable binding to the Sec61 channel, as determined by evaluating ligand and residue flexibility, compactness, contact frequency, motion pathways, free energy, and other relevant parameters. Synthetic routes for these four analogs were proposed for future studies. The results of this study offer a new perspective on developing drugs to inhibit HIV entry.

Anti-AIDS Agents 82: Synthesis of Seco-(3′R,4′r)-3′,4′-di-o-(s)-camphanoyl-(+)-cis-khellactone (DCK) Derivatives As Novel Anti-Hiv Agents

Anti-Aids Agents 84. Synthesis and Anti-Human Immunodeficiency Virus (hiv) Activity of 2 '-Monomethyl-4-methyl- and 1 '-Thia-4-methyl-(3 ' R,4 ' R)-3 ',4 '-Di-o-(s)-camphanoyl-(+)-cis-khellactone (dck) Analogs

Anti-AIDS Agents 86. Synthesis and Anti-Hiv Evaluation of 2′,3′-Seco-3′-nor DCP and DCK Analogues

Anti-AIDS agents. Part 56: Synthesis and anti-HIV activity of 7-thia-di-O-(−)-camphanoyl-(+)-cis-khellactone (7-thia-DCK) analogs

Anti-AIDS Agents. Part 62: Anti-HIV Activity of 2′-Substituted 4-Methyl-3′,4′-di-o-(−)-camphanoyl-(+)-cis-khellactone (4-Methyl DCK) Analogs

Anti-AIDS Agents 87. New Bio-Isosteric Dicamphanoyl-Dihydropyranochromone (DCP) and Dicamphanoyl-Khellactone (DCK) Analogues with Potent Anti-Hiv Activity

Anti-Aids Agents 72. Bioisosteres (7-Carbon-dcks) of the Potent Anti-Hiv Lead Dck

Computational Studies and Drug Design for HIV-1 Reverse Transcriptase Inhibitors of 3′, 4′-Di-o-(s)-camphanoyl-(+)-cis-khellactone (DCK) Analogs.

Development and Preclinical Studies of Broad-Spectrum Anti-Hiv Agent (3'R,4'r)-3-cyanomethyl-4-methyl-3',4'-di-o-(s)-camphanoyl-(+)-cis-khellactone (3-Cyanomethyl-4-methyl-dck).

Optimization of the Antiviral Potency and Lipophilicity of Halogenated 2,6‐diarylpyridinamines As a Novel Class of HIV‐1 NNRTIS

Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors

Cutting-edge Bioinformatics strategies for synthesizing Cyclotriazadisulfonamide (CADA) analogs in next-Generation HIV therapies

Synthesis and Anti-HIV-1 Activity Evaluation of 5-Alkyl-2-alkylthio-6-(arylcarbonyl or Α-Cyanoarylmethyl)-3,4-dihydropyrimidin-4(3h)-ones As Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2- d]pyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Design, Synthesis, and Biological Evaluation

Structural Modifications of Dapy Analogues with Potent Anti-Hiv-1 Activity

Chemical space exploration of novel naphthyl-carboxamide-diarylpyrimidine derivatives with potent anti-HIV-1 activity

Synthesis and Anti-Hiv Activity of Aryl-2-[(4-Cyanophenyl)Amino]-4-Pyrimidinone Hydrazones As Potent Non-Nucleoside Reverse Transcriptase Inhibitors

Design, synthesis, and biological evaluation of (E)-N′-substitute-4-((4-pyridylpyrimidin-2-yl)amino)benzohydrazide derivatives as novel potential CDK9 inhibitors

Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs.

Synthesis and Biological Evaluation of New Conformationally Restricted S-DABO Hybrids As Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase

Synthesis and Biological Evaluation of Pyridinone Analogues As Novel Potent HIV-1 NNRTIs.